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1. Introduction 
In vertebrates, various signaling pathways are activated in a highly coordinated manner to 
ensure proper development and morphogenesis. Secreted signaling molecules such as FGFs 
(Fibroblast growth factors), BMPs (Bone morphogenetic factors), WNTs (Wingless/int), and 
Hedgehogs play crucial roles in development and morphogenesis by acting over variable 
distances to influence intracellular signaling events in neighboring cells. FGFs are 
polypeptide growth factors with diverse biological functions. The human FGF family 
comprises twenty-two members. The mouse and zebrafish are widely used vertebrate 
models for studying gene function in vivo. The mouse and zebrafish FGF families comprise 
twenty-two and twenty-eight members, respectively. These FGFs can be classified as 
paracrine, endocrine, and intracrine FGFs by their mechanisms of action (Itoh & Ornitz, 
2008). Paracrine FGFs (canonical FGFs) mediate biological responses by binding to and 
activating cell surface tyrosine kinase FGFRs. They act as local paracrine signaling molecules 
and function in multiple developmental processes including differentiation, cell 
proliferation, and migration (Itoh & Ornitz, 2008; Beenken & Mohammadi, 2009). Endocrine 
FGFs are thought to mediate biological responses in an FGFR-dependent manner. However, 
they function over long distances as endocrine hormones (Kharitonenkov, 2009; Itoh, 2010). 
In contrast, intracrine FGFs act as FGFR-independent intracellular molecules that regulate 
the function of voltage-gated sodium channels (Goldfarb et al., 2007; Laezza et al., 2009). 
Targeted mutagenesis of Fgf genes in mice has elucidated their functions in development 
and metabolism. Studies with zebrafish Fgf mutant and knockdown embryos also have 
revealed their functions in development. In addition, evidence for the involvement of FGF 
signaling in hereditary, paraneoplastic, and metabolic diseases has also accumulated. FGF 
signaling disorders contribute to pathological conditions. In this article, we provide a 
succinct review of the FGF family in humans, mice, and zebrafish and their developmental 
physiological and pathophysiological roles.  
2. The human/mouse FGF family 
FGF1 and FGF2 are prototypic FGFs originally isolated from the brain and pituitary as 
mitogens for cultured fibroblasts (Gospodarowicz, 1975; Gospodarowicz, et al., 1978). New 
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FGF proteins have since been isolated as growth factors for cultured cells or been identified 
as oncogene products. In addition, new Fgf genes have been identified by homology-based 
PCR/DNA database searching and as genes responsible for hereditary diseases or cancer 
(Itoh & Ornitz, 2008; Beenken & Mohammadi, 2009; Itoh, 2007; Krejci et al., 2009; Turner & 
Grose, 2010). The human/mouse Fgf family comprises twenty-two members, Fgf1-Fgf23. No 
other Fgf genes have been identified in the human/mouse genome.  
Human/mouse FGFs are proteins of ~150-300 amino acids and have a conserved core of 
~120-amino acids with ~30-60% identity. Fgf15 has not been identified in humans. Fgf19 has 
not been identified in mice. Fgf15 and Fgf19 are likely to be orthologous genes in vertebrates. 
Except for rodents, the orthologs are named Fgf19 in vertebrates (Itoh & Ornitz, 2004; Itoh & 
Ornitz, 2008). In this review, we refer to these genes as Fgf15/19. Phylogenetic analysis 
indicates potential evolutionary relationships in the gene family. However, this alone is not 
sufficient to determine the relationships. Analyzing gene loci on chromosomes gives a more 
precise indication of the evolutionary relationships in a gene family. The gene location 
analysis of the human/mouse Fgf family has identified seven subfamilies; Fgf/1/2/5, Fgf3/4/6, 
Fgf7/10/22, Fgf8/17/18, Fgf9/16/20, Fgf11/12/13/14, and Fgf15/19/21/23 (Itoh & Ornitz, 2004; 
Itoh & Ornitz, 2008). FGFs can also be classified as paracrine, endocrine, and intracrine FGFs 
based on their mechanisms of action (Fig. 1). Paracrine FGFs comprise members of the 
FGF/1/2/5, FGF3/4/6, FGF7/10/22, FGF8/17/18, and FGF9/16/20 subfamilies. They are 
secreted proteins, which mediate biological responses in a paracrine manner. Endocrine 
FGFs, FGF15/19, FGF21, and FGF23, are also secreted proteins. However, they mediate 
biological responses in an endocrine manner. Intracrine FGFs, FGF11-FGF14, are 
intracellular proteins, which mediate biological responses in an intracrine manner (Fig. 2).   
 
 
Paracrine Intracrine
Endocrine Fgf
Target cell
Target cellSignaling cell
Bloodstream
Fgf   Fgf
 
 
Fig. 1. Action mechanisms of Fgfs. Fgfs act on target cells in a paracrine, endocrine , or 
intracrine manner.  
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Fig. 2. Schematic representations of structure. Schematic diagrams of intracrine, paracrine, 
and endocrine FGFs are shown. SP, SP* and HB indicate a cleavable secreted signal 
sequence, an uncleaved bipartite secreted signal sequence, and a heparin-binding site, 
respectively. 
3. Mechanisms of action 
3.1 Paracrine FGFs 
Most paracrine FGFs are secreted proteins with cleavable N-terminal secreted signal 
peptides. However, FGF9, FGF16, and FGF20 have uncleaved bipartite secreted signal 
sequences (Revest et al., 2000). By contrast, FGF1 and FGF2 without N-terminal signal 
sequences are not typical secreted proteins. They might be released from damaged cells or 
by an exocytotic mechanism that is independent of the endoplasmic reticulum-Golgi 
pathway (Mohan et al., 2010; Nickel, 2010). Paracrine FGFs mediate biological responses as 
extracellular proteins by binding to and activating cell surface tyrosine kinase FGFR 
receptors (FGFRs) with heparin/heparan sulfate as a cofactor.  
The human/mouse Fgfr gene family comprises four Fgfr genes, Fgfr1–Fgfr4 (Beenken & 
Mohammadi, 2009; Turner & Grose, 2010). All FGFR proteins are receptor tyrosine kinases 
of ~800 amino acids with an extracellular ligand-binding domain with three 
immunoglobulin-like domains (I, II, and III). Fgfr1–Fgfr3 encode two major versions of 
immunoglobin-like domain III (IIIb and IIIc) generated by alternative splicing that utilizes 
one of two unique exons. The immunoglobulin-like domain III is an essential determinant of 
ligand-binding specificity (Zhang et al., 2006). Thus, seven major FGFR proteins (FGFRs 1b, 
1c, 2b, 2c, 3b, 3c, and 4) with differing ligand-binding specificity are generated from four 
Fgfr genes.  
Paracrine FGFs have a heparin-binding site and interaction with heparin-like molecules is 
necessary for their stable interaction with FGFRs and local signaling (Goetz et al., 2007). 
Paracrine FGFs function in development by influencing the intracellular signaling events of 
neighboring cells from a distance. The range of FGF signaling is regulated in part by affinity 
for extracellular matrix heparan sulfate proteoglycans (Kalinina et al., 2009) and in part by 
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the dimerization of some FGFs (Kalinina et al., 2009; Harada et al., 2009). The binding of 
FGFs to FGFRs induces functional dimerization, receptor transphosphorylation, and the 
activation of four key downstream signaling pathways: RAS-RAF-MAPK, PI3K-AKT, STAT, 
and PLCγ (Beenken & Mohammadi, 2009; Turner & Grose, 2010).  
3.2 Endocrine FGFs 
Endocrine FGFs are also thought to mediate biological responses in an FGFR-dependent 
manner. However, they bind to FGFRs and heparin/heparan sulfate with very low affinity. 
The reduced heparin-binding affinity enables endocrine FGFs to function in an endocrine 
manner (Zhang et al., 2006; Goetz et al., 2007). αKlotho is a single-pass transmembrane 
protein of ~1,000 amino acids with a short cytoplasmic domain. The phenotypes of αKlotho 
knockout mice are very similar to those of Fgf23 knockout mice (Shimada et al., 2004), 
indicating that FGF23 and αKlotho may function in a common signal transduction pathway. 
αKlotho most efficiently binds to and activates FGFR1c among several isoforms of FGFRs in 
cultured cells, suggesting that FGFR1c can transduce an FGF23/αKlotho signal(Urakawa et 
al., 2006). 
βKlotho is a protein that shares structural similarity and characteristics with αKlotho. The 
phenotypes of βKlotho knockout mice overlap those of Fgfr4 knockout mice and Fgf15/19 
knockout mice (Ito et al., 2005; Inagaki et al., 2005). FGF15/19 can bind to a βKlotho-FGFR4 
complex in cultured cells. FGF15/19 also activates FGF signaling in hepatocytes that 
primarily express Fgfr4 (Kurosu et al., 2007). These results indicate FGFR4 to be the primary 
receptor for transduction of an FGF15/19/βKlotho signal. βKlotho is also essential for 
FGF21 signaling in cultured cells (Kharitonenkov et al., 2008). However, Fgf21 knockout 
mouse phenotypes are distinct from βKlotho knockout mouse phenotypes (Ito et al., 2005; 
Hotta et al., 2009). In addition, the administration of recombinant human FGF21 to βKlotho 
knockout mice demonstrated that FGF21 signals can be transduced in the absence of 
βKlotho (Tomiyama et al., 2010). These results indicate the existence of a βKlotho-
independent FGF21 signaling pathway in which undefined cofactors might be involved.  
3.3 Intracrine FGFs 
Intracrine FGFs interact with intracellular domains of voltage-gated sodium channels and 
with a neuronal MAPK scaffold protein, islet-brain-2 (Schoorlemmer & Goldfarb, 2002; 
Goldfarb et al., 2007). The only known role for intracrine FGFs is in regulating the electrical 
excitability of neurons and possibly other cell types (Goldfarb et al., 2007; Xiao et al., 2007; 
Shakkottai et al., 2009; Dover et al., 2010). 
4. Evolutionary history of the human/mouse Fgf gene family 
The FGF signaling system has been conserved throughout metazoan evolution. Two Fgf-like 
genes have been identified in the nematode, C. elegans (Huang & Stern, 2005). Six Fgf-like 
genes, which are potential ancestral genes of the human/mouse Fgf subfamilies, have been 
identified in the ascidian, C. intestinalis (Satou et al., 2002). Ascidians belong to the 
Subphylum Urochordata, the earliest branch in the Phylum Chordata. These results indicate 
that most ancestral genes of the human/mouse Fgf subfamilies were generated by gene 
duplication after the diversion of protostomes and deuterostomes. The evolutionary history 
of the mouse Fgf family has been proposed (Fig. 3) (Itoh & Ornitz, 2008). The ancestral gene 
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of the Fgf family is an ancestral intracrine Fgf gene, Fgf13-like, with a heparin-binding site 
but no secreted signal sequence. An ancestral gene of paracrine Fgfs, Fgf4-like, was generated 
from Fgf13-like by gene duplication during the early stages of metazoan evolution. During 
this evolution, Fgf4-like acquired a secreted signal sequence, thus allowing it to function as a 
paracrine Fgf. Ancestral genes, Fgf5-like, Fgf8-like, Fgf9-like, and Fgf10-like, of paracrine Fgf 
subfamilies were also generated from Fgf4-like by gene duplication after the separation of 
protostomes and deuterostomes. Secreted signal sequences were conserved in Fgf5-like, Fgf8-
like, and Fgf10-like. A cleavable secreted signal sequence also evolved into an uncleaved 
bipartite signal sequence in Fgf9-like. These FGFs with heparin-binding sites function in a 
paracrine manner. In contrast, no ancestral gene of endocrine Fgfs has been identified in 
Ciona intestinalis. The ancestral gene of endocrine Fgfs, Fgf15/19-like, appears to have arisen 
from Fgf4-like by local gene duplication early in vertebrate evolution. During this evolution, 
Fgf15/19-like lost its high affinity heparin-binding capacity, thus allowing it to function in an 
endocrine manner. Conserved gene orders are observed among members of each Fgf 
subfamily, indicating that each subfamily further expanded into three or four members via 
two large-scale genome duplication events (R1 and R2) during the evolution of early 
vertebrates.  
 
Fgf13-like       Fgf11 / Fgf12 / Fgf13 / Fgf14
Fgf4-like
Fgf5-like
Fgf8-like
Fgf9-like
Fgf10-like
Fgf1 / Fgf2 / Fgf5
Fgf8 / Fgf17 / Fgf18
Fgf9 / Fgf16 / Fgf20
Fgf7 / Fgf10 / Fgf22
Fgf15/19-like Fgf15/19 / Fgf21 / Fgf23
 
Fgf3 / Fgf4 / Fgf6
Paracrine Fgf 
Intracrine Fgf 
Endocrine Fgf 
Fgf11a / Fgf11b / Fgf12 / Fgf13 / Fgf14
Fgf1 / Fgf2 / Fgf5
Fgf8a / Fgf8b / Fgf17 / Fgf18a / Fgf18b / Fgf24
Fgf16 / Fgf20a / Fgf20b
Fgf7 / Fgf10a / Fgf10b / Fgf22
Fgf3 / Fgf4 / Fgf6a / Fgf6b
Fgf15/19 / Fgf21 / Fgf23
Human/Mouse Zebrafish
Gene duplication Genome duplication (R1 & R2) Genome duplication (R3)  
Fig. 3. The functional evolutionary history of the human/mouse/zebrafish Fgf gene family. 
Fgf13-like is the ancestral gene of the Fgf family. Fgf4-like was generated from Fgf13-like by 
gene duplication during the early stages of metazoan evolution. Fgf5-like, Fgf8-like, Fgf9-like, 
and Fgf10-like were generated from Fgf4-like by gene duplication. Fgf15/19-like was also 
generated from Fgf4-like by local gene duplication. Each subfamily further expanded into 
three or four members via two genome duplication events (R1 &R2) during the evolution of 
early vertebrates. The zebrafish Fgf family further expanded via an additional genome 
duplication event (R3) shortly after the teleost radiation. 
5. The zebrafish FGF family 
Almost all zebrafish orthologs of human/mouse Fgf genes except for Fgf9 have been 
identified. In addition, Fgf24 has been identified in zebrafish as well as all teleosts examined 
including the stickleback, medaka, and puffer fish. However, Fgf24 has not been identified 
in all tetrapods examined. These results indicate that Fgf9 and Fgf24 were lost in the teleost 
lineage and tetrapod lineage during evolution, respectively. Zebrafish also has six 
additional Fgf genes including Fgf6b, Fgf8b, fgf10b, fgf13b, fgf18b, and fgf20b. The zebrafish Fgf 
family comprises twenty-eight members. Analysis of the location of the additional genes 
www.intechopen.com
 
Human Genetic Diseases 
 
42
indicates that they are paralogs (Fig. 3) (Itoh & Konsihi, 2007). Comparisons of mammalian 
genes with genes of teleost fish have shown that in teleosts, including zebrafish, there are 
often two homologs of the mammalian equivalent. This suggests that there has been an 
additional genome duplication event (R3) shortly after the teleost radiation. This duplication 
must have been either a partial or a whole genome duplication followed by rapid gene loss 
because gene duplications account for only ~20% of the zebrafish genes examined 
(Nusslein-Volhard et al., 2002). Zebrafish Fgf paralogs were also generated by genome 
duplication.  
6. Physiological roles of FGFs indicated by Fgf knockout mouse phenotypes 
The mouse is a widely used mammalian model for studying functions of genes. Gene 
functions can be effectively blocked in mice by targeted disruption of genes. Gene knockout 
mouse phenotypes have indicated their physiological functions. Most Fgf genes have been 
disrupted in mice. Phenotypes range from early embryonic lethality to changes in adult 
physiology (Table 1). Paracrine, endocrine, and intracrine FGFs mostly play roles in 
development, and metabolism, and neuronal functions, respectively.  
6.1 Paracrine Fgfs  
Paracrine FGFs are a major FGF group, canonical FGFs, including FGF1-FGF10, FGF16-
FGF18, FGF20, and FGF22. Knockout mouse phenotypes mostly indicate roles as 
growth/differentiation factors. Fgf1 knockout mice are viable and normal (Miller, et al., 
2000). Fgf2 knockout mice are also viable, but have decreased vascular tone and reduced 
numbers of neurons in deep cortical layers (Raballo et al., 2000; Zhou et al., 1998; Dono et al., 
1998). In addition, Fgf2 knockout mice show impaired recovery from ischemic injury to the 
heart (House et al., 2003; Virag et al., 2007). Fgf3 knockout mice are viable, but have 
phenotypes that include inner ear agenesis and dysgenesis, microtia, and microdontia 
(Mansour et al., 1993; Alvarez et al., 2003; Tekin et al., 2007)). Fgf4 and Fgf8 knockout mice 
die at early embryonic stages. Fgf4 and Fgf8 have essential roles in blastocyst formation and 
gastrulation, respectively (Feldman  et al., 1995; Sun et al., 1999). Conditional inactivation of 
Fgf8 has identified additional roles in limb bud development and organogenesis. Fgf5, Fgf6, 
and Fgf7 knockout mice are viable. Abnormal long hair is observed in Fgf5 knockout mice 
(Hébert et al., 1994). Fgf6 knockout mice have defects in muscle regeneration (Floss et al., 
1997). Fgf7 knockout mice have impaired hair and kidney development (Guo et al., 1996; 
Qiao et al., 1999). Fgf9, Fgf10, and Fgf18 knockout mice die shortly after birth. Fgf10 is critical 
for epithelial-mesenchymal interactions necessary for the development of epithelial 
components of multiple organs (Min et al., 1998; Sekine et al., 1999; Ohuchi et al., 2000; 
Sakaue et al., 2002). Fgf9 and Fgf18 have essential roles in the development of mesenchymal 
components of multiple organs (Colvin et al., 2001a,b; Colvin et al., 2001; Ohbayashi et al., 
2002; Liu et ,al. 2002; Usui et al., 2004; Hung et al., 2007). Fgf16 knockout mice on a C57BL/6 
genetic background are viable, but have impaired embryonic cardiomyocyte proliferation 
(Hotta et al., 2008). Fgf16 knockout phenotypes may be more severe on a Black Swiss genetic 
background where they die at embryonic day (E) 10.5 with severely impaired cardiac and 
facial development (Lu et al., 2008; Lu et al., 2010). Fgf17 and Fgf22 knockout mice are viable, 
but show impaired hindbrain development and impaired synaptic differentiation, 
respectively (Xu et al., 2000; Terauchi et al., 2010). In addition, Fgf22 knockout mice also 
show a clear delay in weight gain upon sexual maturity (Grose et al., unpublished data). 
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Fgf20 knockout mice are viable but have profound hearing loss (Ornitz et al., unpublished 
data). 
 
FGF    Physiological roles 
FGF1 None identified 
FGF2 Loss of vascular tone, slight loss of cortical neurons, defects in heart repair 
FGF3 Inner ear agenesis, microtia, microdontia 
FGF4 Defects in blastocyst formation  
FGF5 Abnormal long hair 
FGF6 Defective muscle regeneration 
FGF7 Impaired hair and kidney development 
FGF8 Defects in gastrulation, limb development, organogenesis 
FGF9 Impaired multiple organ development 
FGF10 Impaired multiple organ development 
FGF11 – 
FGF12 None identified, functional redundancy with Fgf14 
FGF13 – 
FGF14 Ataxia, paraoxysmal hyperkinetic movement disorder 
FGF15/19 * Impaired cardiac outflow tract morphogenesis and bile acid metabolism 
FGF16 
Impaired cardiac and facial development 
Impaired embryonic cardiomyocte proliferation 
FGF17 Impaired hindbrain development 
FGF18 Impaired multiple organ development 
FGF20 Impaired inner ear development 
FGF21 Impaired lipid metabolism 
FGF22 Impaired synapse differentiation and delay in weight gain 
FGF23 Impaired phosphate and vitamin D metabolism 
Table 1. Physiological roles of FGFs indicated by Fgf knockout mice Phenotypes of most Fgf 
knockout mice have been published. Phenotypes of Fgf11, Fgf13, and Fgf20 knockout mice 
have not been published. *Fgf15 is referred to as Fg15/19.  
Although roles of paracrine FGFs in embryogenesis have been revealed from knockout 
mouse phenotypes, their contributions to adult physiology remain relatively unexplored. 
The widespread expression of paracrine Fgf genes in adult tissues suggests multiple roles in 
tissue homeostasis and repair (Fon Tacer et al., 2010). Emerging reports indicate homeostatic 
and regenerative roles for paracrine FGF signaling (Böhm et al., 2010; Yang et al., 2010). 
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6.2 Endocrine Fgfs  
Endocrine FGFs, FGF15/19, FGF21, and FGF23, are hormone-like FGFs. Hormones are 
usually responsible for communication between tissues in an endocrine manner. However, 
several hormones are produced in developing tissues that are unrelated to the endocrine 
gland of origin in adults. These hormones are synthesized locally, and serve as 
differentiation factors in embryos (Sanders & Harvey, 2008). Endocrine FGFs also act as 
differentiation factors in embryos and as hormones in adults (Itoh, 2010). 
Fgf15/19 knockout mice develop normally until E10.5, but then gradually die. The 
phenotype indicates that FGF15/19 is required for proper morphogenesis of the cardiac 
outflow tract at embryonic stages (Vincentz et al., 2005). Although most Fgf15/19 knockout 
mice die by postnatal day (P) 7, a few survive and appear phenotypically normal. However, 
fecal bile acid excretion was found to be increased in surviving Fgf15/19 knockout mice, 
indicating that intestinal FGF15/19 plays a crucial role in regulating hepatic bile acid 
synthesis (Inagaki et al., 2005). Fgf21 knockout mice are seemingly normal, but show 
hypertrophy and decreased lipolysis in adipocytes. In contrast, Fgf21 knockout mice fasted 
for 24 h show increased lipolysis in adipocytes and increased serum nonesterified fatty acid 
levels. Their phenotypes indicate that Fgf21 is important for the metabolic regulation of 
lipolysis in white adipose tissue (Hotta et al., 2009). Fgf21 knockout mice fed a ketogenic diet 
show partial impairments in ketogenesis (Badman et al., 2009). However, we have observed 
that ketogenesis is not impaired in Fgf21 knockout mice fed a ketogenic diet (Itoh et al., 
unpublished data). Fgf23 knockout mice survive until birth, but then gradually die, usually 
by 12 weeks of age (Shimada et al., 2004). The mice show hyperphosphatemia and increased 
active vitamin D levels. Fgf23, which is expressed in osteocytes, signals to the kidney where 
it regulates serum phosphate and active vitamin D levels. FGF23 may have other targets 
including the parathyroid gland and osteoblasts (Ben-Dov et al., 2007; Tang et al., 2010). 
6.3 Intracrine Fgfs  
Intracrine FGFs, FGF11-FGF14, are intracellular proteins. Fgf14 knockout mice are viable. 
However, they develop ataxia and a paraoxysmal hyperkinetic movement disorder 
(Goldfarb et al., 2007; Xiao et al., 2007; Shakkottai et al., 2009). In contrast, Fgf12 knockout 
mice are apparently normal. Fgf12/Fgf14 double knockout mice show severe ataxia and 
other neurological deficits (Goldfarb et al., 2007). Phenotypes of Fgf11 and Fgf13 knockout 
mice have not been reported. 
7. Roles of FGFs indicated by Fgf mutated or knockdown zebrafish 
phenotypes 
The zebrafish is also a widely used vertebrate model for studying functions of genes. 
Because zebrafish embryos are small, the fertilization and subsequent embryonic 
development occur externally, and the development is rapid (Nusslein-Volhard et al., 2002), 
phenotypes of zebrafish embryos in which the functions of genes are blocked–the knockout 
of which is lethal at early embryonic stages in mice–can be potentially analyzed. In a large-
scale screening, many zebrafish mutants, which were mutagenized with ethylnitrosourea, 
displaying distinct phenotypes in embryos were generated (Haffter et al., 1996). 
Furthermore, antisense morpholino oligonucleotides can easily block the functions of 
multiple genes in zebrafish embryos (Nasevicius & Ekker, 2000). Therefore the zebrafish is 
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expected to be a useful vertebrate model for studying physiological functions of Fgf genes in 
vivo.  
7.1 Paracrine FGFs 
Several zebrafish paracrine Fgf mutants have been generated by mutagenesis with 
ethylnitrosourea. acerebellar is a mutation of Fgf8. acerebellar embryos lack a cerebellum and 
the midbrain-hindbrain boundary organizer (Reifers et al., 1998). ikarus is a mutation of 
Fgf24. ikarus embryos lack pectoral fin buds (Fischer et al., 2003). daedalus is a mutation of 
Fgf10. Daedalus embryos have no pectoral fin buds either and a severely dysmorphic 
hepatopancreatic ductal system (Norton et al., 2005; Dong et al., 2007). devoid of blastema is a 
mutation of Fgf20a. devoid of blastema embryos have no pectoral fin buds (Whitehead et al., 
2005). These results indicate that zebrafish fgfs also play crucial roles in development. 
Several paracrine Fgf knockdown zebrafish embryos were generated using antisense 
morpholino oligonucleotides. Phenotypes of these embryos indicate roles of Fgfs in 
zebrafish. FGF1 is required for normal differentiation of erythrocytes (Songhet et al., 2007). 
FGF3 and FGF8 are required together for formation of the otic placode and vesicle (Maroon 
et al., 2002). FGF4 is required for left-right patterning of visceral organs (Yamauchi et al., 
2009). In addition, FGF16 is also required for the fin buds to form (Nomura et al., 2006).  
7.2 Endocrine FGFs 
Fgf15/19 and Fgf21 knockdown zebrafish embryos were generated using antisense 
morpholino oligonucleotides. FGF15/19 and FGF21 are required for the forebrain and eye to 
develop (Miyake et al., 2005; Nakayama et al., 2008), and hematopoiesis (Yamauchi et al., 
2006).  
8. FGF signaling disorders in human diseases  
As described above, FGF signaling is crucial to development, metabolism, and neuronal 
functions as paracrine, endocrine, and intracrine factors. In addition, FGF signaling 
disorders also result in human hereditary, paraneoplastic, and metabolic diseases. 
8.1 Paracrine FGFs  
Michel aplasia is a unique autosomal recessive syndrome characterized by type I microtia, 
microdontia, and profound congenital deafness associated with a complete absence of inner 
ear structures. Michel aplasia is caused by mutations in Fgf3 (Tekin et al., 2007). Nonsense 
mutations in Fgf8 are found in familial isolated hypogonadotropic hypogonadism with 
variable degrees of gonadotropin-releasing hormone deficiency and olfactory phenotypes. 
These findings confirm that loss-of-function mutations in Fgf8 cause human gonadotropin-
releasing hormone deficiency (Trarbach et al., 2010). Cleft lip and/or palate (CLP) appear 
when the two halves of the palatal shelves fail to fuse completely. A missense mutation in 
Fgf8 was found in a patient with CLP. This mutation is predicted to cause loss-of-function 
by destabilizing the N-terminal conformation, which is important for FGFR binding affinity 
and specificity (Riley et al., 2007). Aplasia of lacrimal and salivary glands (ALSG) is an 
autosomal dominant congenital anomaly characterized by aplasia, atresia, or hypoplasia of 
the lacrimal and salivary systems. Lacrimo-auriculo-dento-digital syndrome (LADD) is an 
autosomal-dominant multiple congenital anomaly disorder characterized by aplasia, atresia, 
or hypoplasia of the lacrimal and salivary systems, cup-shaped ears, hearing loss, and 
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dental and digital anomalies. Both ALSG and LADD are caused by Fgf10 mutations 
(Entesarian et al., 2007; Rohmann et al., 2006). Fgf20 was originally identified as a 
neurotrophic factor preferentially expressed in dopaminergic neurons within the substantia 
nigra pars compacta of rat brain (Ohmachi et al., 2003). Parkinson disease (PD) is caused by 
a pathogenic process responsible for the loss of dopaminergic neurons within the substantia 
nigra pars compacta. A pedigree disequilibrium test and a case-control association study 
indicated that Fgf20 is potentially a risk factor for PD (Gao et al., 2008).   
8.2 Endocrine FGFs  
Serum FGF15/19 levels are markedly increased in patients with extrahepatic cholestasis 
caused by a pancreatic tumor. FGF15/19 is abundantly expressed in the liver of cholestatic 
patients, but not in the normal liver. FGF15/19 signaling may be involved in some of the 
adaptations that protect the liver against bile salt toxicity (Schaap et al., 2009). Serum 
FGF15/19 levels are also significantly increased in patients on chronic hemodialysis (Reiche 
et al., 2010). Nonalcoholic fatty liver disease (NAFLD) is a hepatic manifestation of 
metabolic syndrome, and ranges from simple fatty liver to nonalcoholic steatohepatitis. Its 
prevalence has increased dramatically over recent years in developed countries (Morris-Stiff 
& Feldstein, 2010). The pathophysiological hallmark of NAFLD is insulin resistance. NAFLD 
may increase the risk of type 2 diabetes and atheroclerosis (Bugianesi et al., 2010). Hepatic 
lipid metabolism is disturbed in patients with NAFLD. The hepatic response to FGF15/19 is 
impaired in NAFLD patients with insulin resistance. This impaired response may contribute 
to the disturbance of lipid homeostasis in NAFLD (Schreuder et al., 2010).  
Serum FGF21 levels are significantly increased in NAFLD (Yilmaz et al., 2010; Dushay et al., 
2010; Li et al., 2010). Serum FGF21 levels are positively correlated with intrahepatic 
triglyceride levels (Li et al., 2010). As NAFLD is now recognized as a major public health 
problem, reliable biomarkers for NEFLD are needed. Serum FGF21 levels might be useful as 
a biomarker for NEFLD (Morris-Stiff & Feldstein, 2010). Type 2 diabetes connected with 
visceral obesity and insulin resistance has become a global health concern. Serum FGF21 
levels are increased in patients with type 2 diabetes, gestational diabetes, and obesity, 
indicating FGF21 to be a potential new marker in patients with type 2 diabetes (Table 1) 
(Chen et al., 2008; Zhang et al., 2008; Chavez et al., 2009; Mraz et al., 2009; Stein et al., 2010; 
Matuszek et al., 2010). Serum FGF21 levels are independently associated with markers of 
insulin resistance and an adverse lipid profile (Chen et al., 2008; Stein et al., 2010). The up-
regulation of serum FGF21 levels might be a compensatory mechanism to improve glucose 
metabolism when insulin resistance is present. Impaired glucose tolerance (IGT) is an 
important category of prediabetes. Serum FGF21 levels were also increased in Chinese 
subjects with IGT, however, they did not correlate with insulin resistance (Li et al., 2009). 
Cushing's syndrome is a hormone disorder caused by high levels of cortisol 
(hypercortisolism) in the blood. Patients with Cushing's syndrome frequently suffer from 
visceral obesity, insulin resistance/diabetes, and other abnormalities similarly to patients 
with metabolic syndrome. Serum FGF21 levels are also increased in patients with Cushing’s 
syndrome. The increased FGF21 levels are due to excessive fat accumulation and related 
metabolic abnormalities rather than a direct effect of cortical on FGF21 production 
(Durovcová et al., 2010). Lipodystrophy is a common alteration in HIV-1-infected patients 
under anti-retroviral treatment. This syndrome is usually associated with peripheral 
lipoatrophy, central adiposity, and, in some cases, lipomatosis, as well as systemic insulin 
resistance and hyperlipidemia (Villarroya et al., 2007). Serum FGF21 levels are increased in 
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HIV-1-infected patients with lipodystrophy. This increase is closely associated with insulin 
resistance, metabolic syndrome, and markers of liver damage. FGF21 might be a biomarker 
of altered metabolism in HIV-1-infected, antiretroviral-treated patients (Domingo et al., 
2010). Serum FGF21 levels correlate with renal function and are markedly increased in 
chronic kidney disease patients receiving hemodialysis, suggesting a possible link between 
their FGF21 levels and renal function (Stein et al., 2009). Patients with end-stage renal 
disease (ESRD) show insulin resistance. Serum FGF21 levels are also markedly increased in 
patients with ESRD, suggesting FGF21 to play a role in insulin resistance in these patients 
(Han et al., 2010).  
Autosomal dominant hypophosphatemic rickets (AHDR) is caused by gain-of-function 
mutations of Fgf23 (ADHR Consortium, 2000). FGF23 is partially cleaved by intracellular 
proteolysis. The cleaved forms lose their biological activity. Fgf23 mutations in ADHR result 
in impaired proteolysis of FGF23 and increased serum levels of active FGF23 (White et al., 
2001). Reduced FGF23 signaling also causes human hereditary diseases. Familial tumoral 
calcinosis (FTC) is characterized by ectopic calcification and hyperphosphatemia. Loss-of-
function mutations of Fgf23 result in FTC. These mutations destabilize the tertiary structure 
of FGF23 and increase its susceptibility to degradation (Benet-Pagès et al., 2005). Tumors 
that over-produce FGF23 also cause tumor-induced osteomalacia, which is a paraneoplasitc 
disease characterized by hypophosphatemia caused by renal phosphate wasting (Shimada 
et al., 2001).  Serum FGF23 levels are also greatly increased in patients with renal failure, 
partly owing to decreased renal clearance. These results suggest that FGF23 has a 
compensatory role in the disease (Larsson et al., 2003). 
8.3 Intracrine FGFs  
Börjeson-Forssman-Lehmann syndrome (BFLS) is a syndromic X-linked mental retardation 
disease. Fgf13 is a candidate causative gene for BFLS (Gecz et al., 1999). Hereditary 
spinocerebellar ataxias (SCAs) are a clinically and genetically heterogeneous group of 
neurodegenerative disorders. One SCA with early-onset tremors, dyskinesia, and slowly 
progressive cerebellar ataxia is caused by Fgf14 mutations (van Swieten et al., 2003; Brusse et 
al., 2006; Misceo et al., 2009).  
9. Conclusion 
The human/mouse FGF family comprises twenty-two members, which were generated by 
gene duplication after the diversion of protostomes and deuterostomes and two genome 
duplication events (R1 and R2) during the evolution of early vertebrates. In contrast, the 
zebrafish FGF family comprises twenty-eight members including several paralogs, which 
were generated by an additional genome duplication event (R3) in the teleost lineage during 
evolution. FGFs are now recognized as proteins with diverse biological functions and act as 
extracellular signaling molecules in a paracrine or endocrine manner or as intracellular 
signaling molecules. Experiments with Fgf knockout mice indicate that FGFs play vital roles 
in development, metabolism, and neuronal functions. Studies with Fgf mutated or 
knockdown zebrafish also indicate that FGFs are crucial to development. In addition, 
research on human diseases indicates that FGF signaling disorders contribute to 
pathological conditions. Secreted signaling molecules such as BMPs, WNTs, and Hedgehogs 
also play crucial roles in development by influencing the intracellular signaling events of 
their neighbors from a distance. FGFs, along with these signaling molecules, have roles in 
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diverse biological processes in multicellular organisms. However, the 
interaction/cooperation of FGFs with BMPs, WNTs, and Hedgehogs mostly remain unclear. 
Further understanding of the roles of FGFs will provide clues to their mechanisms of 
interaction/cooperation. 
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